Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Shares of Novo Nordisk slipped in Monday morning trading ... trial to see how the drug compared to the company's other drugs, Ozempic, which is approved by the FDA for diabetes, and Wegovy ...

IT’S hard to imagine a time when the word ‘Ozempic’ wasn’t part of our vocabulary.  For years, celebs have embraced the ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...

single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s Wegovy and ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE ... with capacity for 100 million pens annually by 2025. With a market cap ...

the active ingredient of Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief executive said on Friday. The patent protection for semaglutide ...